|
The Neuroscience Steering Committee focuses on selecting, developing, and validating biomarkers of relevance to psychiatric disorders, neurodegenerative diseases, and related disorders.
Assembled by The Biomarkers Consortium Executive Committee, the Neuroscience Steering Committee is co-chaired by: Huda Akil, Ph.D., M.A., Professor of Neuroscience and Psychiatry and Co-Director, Molecular and Behavioral Neuroscience Institute, University of Michigan, and William Potter, M.D., Ph.D., Vice President, Translational Neuroscience, Merck & Co., Inc. The Neuroscience Steering Committee meets regularly, with one face-to-face meeting per year. The members of the Neuroscience Steering Committee include: - Irina Antonijevic, M.D., Ph.D., Lundbeck
- Wade Berrettini, M.D., Ph.D., University of Pennsylvania
- Beth Borowsky, Ph.D., High Q Foundation
- Linda Brady, Ph.D., National Institute of Mental Health
- Neil Buckholtz, Ph.D., National Institute of Aging
- Maria Carrillo, Ph.D., Alzheimer's Association
- Ken Davis, M.D., Mount Sinai School of Medicine
- Enrico Domenici, M.D., GlaxoSmithKline
- Robert Dunn, M.D., Ph.D., Pfizer, Inc.
- Thomas P. Finn, Ph.D., Center for Biologics Evaluation and Research, FDA
- Baltazar Gomez-Mancilla, M.D., Ph.D., Novartis
- Richard Hargreaves, Ph.D., Merck & Co., Inc.
- Franz F. Hefti, Ph.D., Avid Radiopharmaceuticals, Inc.
- Stephen Kanes, M.D., AstraZeneca
- Robert M. Kessler, M.D., Vanderbilt University Medical Center
- Walter J. Koroshetz, M.D., National Institute of Neurological Disorders and Stroke
- Hank F. Kung, Ph.D., University of Pennsylvania
- Tom Laughren, M.D., Center for Drug Evaluation Research, FDA
- Chi-Ming Lee, M.D., AstraZeneca
- Marilyn M. Lightfoote, M.D., Center for Devices and Radiological Health, FDA
- Andrew Lockhart, M.D., GlaxoSmithKline
- Husseini K. Manji, M.D., Johnson & Johnson Pharmaceutical Research & Development
- Bill Matthew, Ph.D., National Institute of Neurological Disorders and Stroke
- Robert N. McBurney, Ph.D., BG Medicine, Inc.
- James P. McNulty, National Alliance on Mental Illness
- Susanne Ostrowitzki, M.D., Roche Palo Alto LLC
- Scott Reines, M.D., Ph.D., Consultant, Foundation for NIH
- Howard Schulman, Ph.D., PPD, Inc.
- Belinda Seto, Ph.D., National Institute of Biomedical Imaging and Bioengineering
- Todd Sherer, Ph.D., Michael J. Fox Foundation
- David Shurtleff, Ph.D., National Institute on Drug Abuse
- Eric Siemers, M.D., Eli Lilly and Company
- J. Randall Slemmon, Ph.D., Bristol-Meyers Squibb Company
- A. Gregory Sorenson, M.D., Harvard Medical School
- Chris Turck, Ph.D., Max Planck Institute of Psychiatry
- Jeffrey Waring, Ph.D., Abbott Laboratories
- Paola Zaratin, Ph.D., Merck Serono
|
